Mostrar el registro sencillo del ítem

Artículo

dc.creatorde la Torre, Cristinaes
dc.creatorJátiva, Pabloes
dc.creatorPosadas, Inmaculadaes
dc.creatorManzanares, Daríoes
dc.creatorJiménez Blanco, José Luises
dc.creatorOrtiz Mellet, Carmenes
dc.creatorGarcía Fernández, José Manueles
dc.creatorCeña, Valentínes
dc.date.accessioned2023-04-14T13:33:13Z
dc.date.available2023-04-14T13:33:13Z
dc.date.issued2022
dc.identifier.citationde la Torre, C., Játiva, P., Posadas, I., Manzanares, D., Jiménez Blanco, J.L., Ortiz Mellet, C.,...,Ceña, V. (2022). A β-Cyclodextrin-Based Nanoparticle with Very High Transfection Efficiency Unveils siRNA-Activated TLR3 Responses in Human Prostate Cancer Cells. Pharmaceutics, 14 (11). https://doi.org/10.3390/pharmaceutics14112424.
dc.identifier.issn1999-4923es
dc.identifier.urihttps://hdl.handle.net/11441/144422
dc.description.abstractSynthetic double-stranded small interfering RNAs (siRNAs) mimic interference RNAs (RNAi) and can bind target mRNAs with a high degree of specificity, leading to selective knockdown of the proteins they encode. However, siRNAs are very labile and must be both protected and transported by nanoparticles to be efficiently delivered into cells. In this work, we used a Janus-type polycationic amphiphilic β-cyclodextrin derivative to efficiently transfect siRNAs targeting mRNAs encoding mitogen-activated protein kinase (p42-MAPK) or Ras homolog enriched in brain (Rheb) into different cancer cell lines as well as astrocytes. We took advantage of this high transfection efficiency to simultaneously knock down p42-MAPK and Rheb to boost docetaxel (DTX)-mediated toxicity in two human prostate cancer cell lines (LNCaP and PC3). We found that double knockdown of p42-MAPK and Rheb increased DTX-toxicity in LNCaP but not in PC3 cells. However, we also observed the same effect when scramble siRNA was used, therefore pointing to an off-target effect. Indeed, we found that the siRNA we used in this work induced toll-like receptor 3 activation, leading to β-interferon production and caspase activation. We believe that this mechanism could be very useful as a general strategy to elicit an immune response against prostate cancer cells.es
dc.description.sponsorshipInstituto de Salud Carlos III AC19/00075es
dc.description.sponsorshipJunta de Castilla-La Mancha SBPLY/19/180501/000067es
dc.description.sponsorshipEuropean Cooperation in Science and Technology CA17140es
dc.description.sponsorshipJunta de Andalucía P20_00166es
dc.description.sponsorshipMinisterio de Ciencia e Innovación PID2020-120134RB-I00, RTI2018-097609-B-C21, PID2021-124247OB-C21, PID2019-105858RB-I00es
dc.description.sponsorshipERANET NANO4GLIOes
dc.formatapplication/pdfes
dc.format.extent18 p.es
dc.language.isoenges
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)es
dc.relation.ispartofPharmaceutics, 14 (11).
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectGlioblastomaes
dc.subjectp42-MAPKes
dc.subjectProstate canceres
dc.subjectRhebes
dc.subjectsiRNAes
dc.subjectβ-cyclodextrines
dc.titleA β-Cyclodextrin-Based Nanoparticle with Very High Transfection Efficiency Unveils siRNA-Activated TLR3 Responses in Human Prostate Cancer Cellses
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Química orgánicaes
dc.relation.projectIDPID2020-120134RB-I00es
dc.relation.projectIDAC19/00075es
dc.relation.projectIDSBPLY/19/180501/000067es
dc.relation.projectIDCA17140es
dc.relation.projectIDRTI2018-097609-B-C21es
dc.relation.projectIDPID2021-124247OB-C21es
dc.relation.projectIDPID2019-105858RB-I00es
dc.relation.projectIDP20_00166es
dc.relation.projectIDNANO4GLIOes
dc.relation.publisherversionhttps://doi.org/10.3390/pharmaceutics14112424es
dc.identifier.doi10.3390/pharmaceutics14112424es
dc.journaltitlePharmaceuticses
dc.publication.volumen14es
dc.publication.issue11es
dc.contributor.funderMinisterio de Ciencia, Innovación y Universidades (MICINN). Españaes
dc.contributor.funderAgencia Estatal de Investigación. Españaes
dc.contributor.funderInstituto de Salud Carlos IIIes
dc.contributor.funderEuronanomed Programes
dc.contributor.funderJunta de Castilla-La Manchaes
dc.contributor.funderJunta de Andalucíaes
dc.contributor.funderEuropean Cooperation in Science and Technology (COST)es
dc.contributor.funderEuropean Regional Development Fundes

FicherosTamañoFormatoVerDescripción
A β-Cyclodextrin-Based Nanopar ...3.107MbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Atribución 4.0 Internacional